Provided are an anti-tumor fusion protein, a preparation method therefor and an application thereof. Specifically, the fusion protein contacts a CPP element, an optional linking element, and a SH2 domain of SHP2 or SHP1 or an active fragment thereof. The obtained fusion protein has an extremely excellent anti-tumor effect.

The present invention provides peptides of general formula (I) and salts thereof, wherein: R.sub.1 and R.sub.2, taken together, form a birradical linker; and R.sub.2′ is hydrogen; or, alternatively, R.sub.1 is selected from hydrogen, —C(═O)—CH.sub.2—NH—C(═O)—(C.sub.1-C.sub.5)alkyl, and —C(═O)—(C.sub.1-C.sub.20)alkyl; one of R.sub.2 and R.sub.2′ is hydrogen and the other is selected from —C(═O)NR.sub.3R.sub.4, and —C(═O)OH; and R.sub.3 and R.sub.4 are same or different and are selected from hydrogen and (C.sub.1-C.sub.10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both. ##STR00001##

The present invention provides nucleic acids encoding a fusion protein comprising a nucleotide sequence encoding GRIM-19 or a biologically active fragment or derivative thereof and a nucleotide sequence encoding a protein transduction domain. Proteins encoded by the nucleic acids, pharmaceutical compositions and methods of treatment are also provided. The invention also provides viral vectors comprising GRIM-19 or a biologically active fragment or derivative thereof, pharmaceutical compositions and methods of treatment using the same.

The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.

A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-ß targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.

The present invention provides oligopeptidic compounds comprising a first oligopeptidic component derived from SLAMF1 and a second oligopeptidic component which is a cell-penetrating peptide. The oligopeptidic compounds provided have been found unexpectedly to block signalling from TLR4, TLR7, TLR8 and TLR9 in response to stimulus by their ligands, and also to display an anti-proliferative effect on cancer cells. The oligopeptidic compounds provided may be used in therapy for conditions associated with overactive immune responses, such as sepsis, and for treatment of cancer.

Provided herein are CRIS-PR/Cas9 complexes and methods of using same.

Disclosed herein are new peptide inhibitors against beta-lactam resistance that can improve the efficacy of currently available antibiotics. Methods of using the peptide inhibitors for treating bacterial infections are also disclosed.

An isolated polypeptide derived from human sortilin, including an amino acid sequence which has at least 80% identity with the sequence SEQ ID NO 2 Val Leu Ile Val Lys Lys Tyr Val Cys Gly Gly Arg Phe Leu Val Mis Arg Tyr Ser Val Leu Gin Gin Mis Ala Glu Ala Asn Gly Val Asp Gly Val Asp Ala Leu Asp Thr Ala Ser Mis Thr Asn Lys Ser Gly Tyr Mis Asp Asp Ser Asp Glu Asp Leu Leu Glu on condition that the polypeptide does not contain the sequence SEQ ID NO 3 or a sequence having at least 80% identity with the aforementioned sequence SEQ ID NO 3, for use as a drug.

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.